Cost of Revenue Trends: Merck & Co., Inc. vs BioCryst Pharmaceuticals, Inc.

Comparing cost trends of Merck & BioCryst from 2014-2023

__timestampBioCryst Pharmaceuticals, Inc.Merck & Co., Inc.
Wednesday, January 1, 201412200016768000000
Thursday, January 1, 2015189600014934000000
Friday, January 1, 2016269900013891000000
Sunday, January 1, 2017170200012775000000
Monday, January 1, 201847100013509000000
Tuesday, January 1, 2019410100014112000000
Wednesday, January 1, 2020167600013618000000
Friday, January 1, 2021726400013626000000
Saturday, January 1, 2022659400017411000000
Sunday, January 1, 2023466100016126000000
Loading chart...

Igniting the spark of knowledge

Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This analysis contrasts the cost of revenue trends for Merck & Co., Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Merck, a titan in the industry, consistently reported costs in the range of $13 billion to $17 billion annually, reflecting its expansive operations and market reach. In contrast, BioCryst, a smaller player, showed a more volatile pattern, with costs ranging from $122,000 in 2014 to a peak of $7.3 million in 2021. Notably, Merck's cost of revenue decreased by approximately 4% from 2022 to 2023, while BioCryst saw a 29% drop in the same period. These trends highlight the differing scales and operational strategies of these companies, offering insights into their financial health and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025